Chapter review

Fitzgerald PMHNP board review. ch10. Schizophrenia. This is drive 5 of 6. When I say Pause. Answer. wait, then I will give the answer. New section. Clozapine, LAIs, and treatment-resistance rules. Topic. Long-Acting Injectables (LAI). Bottom Line Summary. * **Primary indication**: Long-acting injectables (**LAIs**) are indicated for patients with **schizophrenia** who exhibit partial or full medication non-adherence, recurrent relapses, or personal preference for non-daily dosing. * **First-generation LAIs**: Include **haloperidol decanoate** and **fluphenazine decanoate**, which carry a higher risk of extrapyramidal symptoms (**EPS**) and **tardive dyskinesia**. * **Second-generation LAIs**: Include **risperidone** (Consta), **paliperidone palmitate** (**Invega Sustenna**, **Invega Trinza**, **Invega Hafyera**), and **aripiprazole** (Abilify Maintena, Aristada). * **Extended dosing intervals**: **Invega Sustenna** is administered monthly, **Invega Trinza** is administered every 3 months after establishing monthly stability, and **Invega Hafyera** is administered every 6 months. * **Relapse prevention**: Maintenance antipsychotic therapy with **LAIs** reduces the annual relapse rate to under 30 percent, preventing progressive cognitive and functional deterioration. * **Tardive dyskinesia timeline**: Withdrawal emergence or onset of **tardive dyskinesia** occurs within 4 weeks of stopping oral antipsychotics, but can take up to 8 weeks following cessation of a depot **LAI**. * **Prerequisite**: Establishing oral tolerability and clinical response with the matching oral agent is required before initiating an **LAI** formulation. High-Yield Concept Map: Long-Acting Injectables (LAI). * **What it is**: Depot formulations of first- and second-generation antipsychotics administered via deep intramuscular injection to maintain sustained therapeutic plasma drug levels. * **Why boards care**: Non-adherence is the primary driver of psychotic relapse, emergency department visits, and rehospitalization in **schizophrenia**. **LAIs** eliminate covert non-adherence. * **Must know criteria and features**: Up to 20 percent of patients are non-adherent even in structured inpatient settings, and over 50 percent relapse within two years of a first episode. Each relapse causes permanent functional decline. * **Typical board clue**: A patient with recurrent hospitalizations who promises they are taking their daily oral medication, or a patient who stops oral meds due to forgetfulness or lack of insight. * **First-line approach**: Second-generation **LAIs** are preferred over first-generation **LAIs** due to lower **EPS** and **tardive dyskinesia** risk. * **When the answer changes**: If the patient has failed two or more adequate trials of different antipsychotics despite confirmed adherence, switch to **clozapine** rather than another **LAI**. * **Safety alert**: Always confirm oral tolerability before giving the first injection to prevent prolonged adverse reactions. **Tardive dyskinesia** signs can take up to 8 weeks to manifest after discontinuing a depot **LAI**. Spoken Teaching and Clinical Rules. Signpost Rules. * **First-line**: Second-generation antipsychotics (**SGAs**) are **first-line** agents for **schizophrenia**. When non-adherence threatens stability or causes repeated relapse, converting to a second-generation **LAI** is the **first-line** secondary prevention strategy. * **Safety alert**: **Tardive dyskinesia** monitoring with the **AIMS** scale must occur at baseline and every 3 to 6 months. Remember that depot formulations clear slowly, so adverse effects or **tardive dyskinesia** emergence may persist or delay onset up to 8 weeks after the last injection. * **Board trap**: Test writers like to present a patient who is relapsing due to medication non-adherence and offer **clozapine** as a choice. **Clozapine** is reserved for true treatment-resistant **schizophrenia** (failure of two or more adequate trials) or severe persistent suicide/violence risk. It is not the correct choice for simple oral non-adherence. The correct move for oral non-adherence is an **LAI**. Dosing Intervals and Formulations. Paliperidone palmitate options illustrate how second-generation **LAIs** offer flexible long-term maintenance: * **Invega Sustenna** is the 1-month monthly formulation. * **Invega Trinza** is the 3-month formulation, used only after a patient is established on **Invega Sustenna** for at least 4 months. * **Invega Hafyera** is the 6-month formulation, administered twice a year for ultra-long-term maintenance. First-generation depots like **haloperidol decanoate** and **fluphenazine decanoate** are typically administered every 2 to 4 weeks. They remain effective options when a patient has responded well to the oral parent drug in the past without developing **EPS**. Sequence for Initiating LAI Therapy. 1. Confirm the diagnosis of **schizophrenia** and identify partial or full oral non-adherence. 2. Administer an oral trial of the target agent to verify tolerability and rule out severe adverse reactions. 3. Calculate the loading and maintenance dose per manufacturer guidelines. 4. Administer the intramuscular injection using z-track technique into the deltoid or gluteal muscle. 5. Provide oral overlapping coverage during the initiation phase as required by the specific drug kinetics. Common Board Traps and Distractor Logic. * **The Clozapine Shortcut Trap** * **Why it looks right**: **Clozapine** is the most effective antipsychotic for severe illness. * **Why it is wrong**: **Clozapine** requires strict **ANC** monitoring, carries risks of agranulocytosis, myocarditis, and severe constipation, and is reserved for treatment resistance, not unconfirmed oral adherence. * **Board rule to remember**: Fix non-adherence with an **LAI** before labeling a patient as treatment-resistant. * **Skipping the Oral Trial** * **Why it looks right**: The patient is acutely psychotic in the ED and needs immediate long-acting control. * **Why it is wrong**: Administering an **LAI** without checking oral tolerability can lead to weeks of unmanageable **EPS**, dystonia, or neuroleptic malignant syndrome (**NMS**) if the patient is hypersensitive. * **Board rule to remember**: Always prove oral tolerability before giving a long-acting depot. Fitzgerald Sample Test Questions. Question 1. A 22-year-old patient is newly diagnosed with **schizophrenia** and is at an outpatient appointment with his parents. Which of the following does the PMHNP realize is the most critical task to complete at this visit? - A. Notify the patient's school or work of the diagnosis. - B. Educate the patient on the importance of medication adherence. - C. Reassure family members of a low risk of suicide attempt. - D. Educate family members of possible increased risk for homicidal tendencies. Pause. Answer. **Best Answer**: B. Educate the patient on the importance of medication adherence. **Why It Is Correct**: Educating the patient on medication adherence is the single most critical task early in treatment to prevent psychotic relapse, rehospitalization, and progressive functional decline. Unreliable oral adherence is the primary indication for converting to a long-acting injectable (**LAI**). **Why the Other Choices Are Wrong**: - A. Disclosing a psychiatric diagnosis to an employer or school without explicit written patient consent violates HIPAA and patient confidentiality. - C. Reassuring the family of low suicide risk is factually incorrect and unsafe, as 20 to 50 percent of patients with **schizophrenia** attempt suicide. - D. Educating on homicidal tendencies is incorrect and stigmatizing because treated patients with **schizophrenia** are no more likely to commit homicide than the general public. **Test-Taking Pearl**: Medication adherence is the single greatest predictor of relapse prevention in **schizophrenia**. When oral adherence fails, **LAI** therapy is the gold-standard intervention. **Concept tested**: Medication adherence and secondary prevention in **schizophrenia**. Question 2. A 22-year-old male diagnosed with paranoid **schizophrenia** has been taking **haloperidol** for the past six months. During this visit, the PMHNP acknowledges involuntary, repetitive muscle movements and excessive eye blinking that were not documented at his last visit. What is the appropriate next course of action? - A. Measure serum ALT and AST. - B. Measure serum creatinine. - C. Administer PHQ-9 questionnaire and compare it to baseline value. - D. Administer AIMS questionnaire and compare it to baseline value. Pause. Answer. **Best Answer**: D. Administer AIMS questionnaire and compare it to baseline value. **Why It Is Correct**: The patient exhibits classic signs of **tardive dyskinesia**, an involuntary movement disorder caused by long-term dopamine blockade from first-generation antipsychotics like **haloperidol**. The **AIMS** tool must be administered to quantify movement severity and track progression. **Why the Other Choices Are Wrong**: - A. Liver transaminases evaluate hepatic injury, not extrapyramidal motor symptoms. - B. Serum creatinine evaluates renal function and is irrelevant to **tardive dyskinesia**. - C. The PHQ-9 measures depressive symptoms, not involuntary motor movements. **Test-Taking Pearl**: Early extrapyramidal symptoms are warning signs for **tardive dyskinesia**. Always perform baseline and periodic **AIMS** testing for patients on long-term antipsychotics or depot **LAIs**. **Concept tested**: **Tardive dyskinesia** assessment using the **AIMS** tool. Question 3. The PMHNP would anticipate that treatment commonly employed to reduce the morbidity of **schizophrenia** would include all of the following EXCEPT: - A. Psychodynamic psychotherapy. - B. Cognitive behavioral therapy. - C. Assertive community treatment. - D. Social skills training. Pause. Answer. **Best Answer**: A. Psychodynamic psychotherapy. **Why It Is Correct**: **Psychodynamic psychotherapy** is not an evidence-based treatment for **schizophrenia** and is contraindicated during active illness because probing unconscious conflicts can exacerbate anxiety and psychotic symptoms. **Why the Other Choices Are Wrong**: - B. Cognitive behavioral therapy (**CBT** for psychosis) helps patients manage persistent auditory hallucinations and delusions. - C. Assertive community treatment (**ACT**) provides multidisciplinary home-based care that improves **LAI** adherence and reduces hospital readmissions. - D. Social skills training restores functional skills and community re-entry. **Test-Taking Pearl**: Boards favor practical, evidence-based psychosocial interventions like **ACT**, **CBT**, and social skills training over insight-oriented psychodynamic therapy for psychotic spectrum disorders. **Concept tested**: Evidence-based psychosocial modalities in **schizophrenia**. Next Study Step. Review **Clozapine Protocol and Absolute Neutrophil Count (ANC) Rules** to master the management of true treatment-resistant **schizophrenia** and severe agranulocytosis monitoring requirements. Next. New section. Medical rule-outs, etiology, and board pearls. Topic. Genetic risk hierarchy. Bottom Line Summary. * **Schizophrenia** genetic risk scales directly with genetic proximity: **monozygotic twins** share a 50% risk, offspring of two affected parents face a 40% risk, offspring of one parent face a 12% risk, non-twin siblings face an 8% risk, and the general population prevalence is 0.7%. * Diagnostic criteria require at least two characteristic symptoms for at least one month, with total continuous disturbance lasting at least six months; at least one symptom must be **delusions**, **hallucinations**, or **disorganized speech**. * **First-line** pharmacotherapy consists of second-generation antipsychotics (**SGAs**) due to lower extrapyramidal symptom (**EPS**) risk, comparable positive symptom efficacy, and superior action on negative symptoms via serotonin 5-HT2A receptor antagonism. * **Safety alert**: **Neuroleptic Malignant Syndrome** (**NMS**) presents as "hot, stiff, and out of it" with severe muscle rigidity, hyperthermia, altered consciousness, autonomic instability, and elevated **serum creatine kinase** (**CK**) above 1000 IU/L; immediate treatment requires drug cessation, supportive care, and **dantrolene**. * **Clozapine** is third-line for treatment-resistant cases, persistent suicidality, or severe aggression; initiation requires an absolute neutrophil count (**ANC**) of at least 1500 per cubic millimeter, with monthly monitoring after one year, and discontinuation if **ANC** falls below 1000. * **Board trap**: Tobacco smoke byproducts induce the **CYP1A2** isoenzyme, reducing blood levels of **clozapine** and **olanzapine**; smoking cessation leads to toxic drug accumulation, whereas resuming smoking drops therapeutic levels and triggers psychotic relapse. * **Board trap**: Patients with **schizophrenia** are no more likely to commit homicide than the general public when medicated, but face a 20% to 50% lifetime suicide attempt rate and a 5% completed suicide rate, especially when experiencing co-occurring **major depressive disorder** or high insight into illness limitations. Genetic Risk Hierarchy and Etiology. * Risk scales directly with genetic proximity. Monozygotic twins demonstrate a 50% risk, which also means a 50% chance of no disease, proving non-genetic environmental factors exist. * Offspring of two parents with **schizophrenia** carry a 40% risk (and a 60% chance of remaining unaffected). Offspring of one affected parent carry a 12% risk. * Non-twin siblings carry an 8% risk. The general population prevalence is 0.7%, affecting men and women equally across all cultures and geographic areas. * Men experience earlier peak onset between ages 10 and 25. Women experience peak onset between ages 25 and 35, with a minor second peak after age 40. Women generally exhibit better social functioning and fewer negative symptoms. * Perinatal and environmental risk factors include birth in winter or spring, maternal influenza exposure, maternal starvation during pregnancy, perinatal hypoxia, advanced paternal age, and obstetric complications. * Etiology involves multi-system neurochemical dysregulation across **dopamine**, **glutamate**, **GABA**, **acetylcholine**, **nicotine**, **norepinephrine**, and **serotonin**. No single brain region or single neurotransmitter accounts for the disorder. Medical Rule-Outs and Differential Diagnostics. * **First-line**: Always rule out physical disease, toxicities, and medication effects before diagnosing primary **schizophrenia**. * **Safety alert**: Organic conditions mimicking psychosis include **neurodegenerative diseases** (Alzheimer disease, Parkinson disease, Huntington disease, multiple sclerosis), **CNS lesions** (temporal lobe epilepsy, neoplasms, head trauma), **vascular disease** (hypertensive encephalopathy), **infections** (neurosyphilis, HIV, Creutzfeldt-Jakob disease, herpes encephalitis), **endocrine/metabolic crises** (Cushing syndrome, Addison disease, hyponatremia, hypoglycemia, uremia), and **vitamin deficiencies** (B12, thiamine, folate). * Medical substances causing psychotic symptoms include **corticosteroids**, **anabolic steroids**, **cimetidine**, **disulfiram**, **amphetamines**, **cocaine**, and **withdrawal** from alcohol or barbiturates. * **Charles Bonnet syndrome** occurs in visually impaired elderly patients, such as those with **macular degeneration** or **diabetic retinopathy**. Patients experience complex visual hallucinations while remaining fully alert, lucid, and aware that the images are unreal, without cognitive decline or psychiatric history. Board Pearls and Psychopharmacology. * **First-line**: **SGAs** (such as **risperidone**, **olanzapine**, **quetiapine**, **aripiprazole**, **ziprasidone**) are preferred over **FGAs** (such as **haloperidol**, **fluphenazine**, **chlorpromazine**) due to reduced risk of **EPS** and **tardive dyskinesia**. * **Board trap**: **FGAs** block dopamine D2 receptors aggressively, causing high rates of acute **dystonia**, **parkinsonism**, and **akathisia**. **Dystonia** requires immediate treatment with parenteral **benztropine** or **diphenhydramine**. **Akathisia** responds best to **propranolol**. * **Tardive dyskinesia** presents with involuntary choreoathetoid movements of the face, tongue, and extremities. Screen using the **Abnormal Involuntary Movement Scale** (**AIMS**). Treat by switching to **clozapine** or **quetiapine**, or adding a **VMAT2 inhibitor** like **valbenazine**. * **Clozapine** carries black box warnings for **agranulocytosis**, severe constipation leading to bowel obstruction, myocarditis, seizures, and orthostatic hypotension. Monitor **ANC** weekly for 6 months, biweekly for 6 months, then monthly. * **Board trap**: Tobacco smoke byproducts (polycyclic aromatic hydrocarbons) induce **CYP1A2**. Smoking decreases **clozapine** and **olanzapine** serum concentrations. Hospitalized patients who quit smoking experience elevated drug levels, whereas resuming smoking after discharge drops serum levels and causes treatment failure. * **Safety alert**: **NMS** mortality reaches 10% to 20%. Characterized by hyperthermia, "lead-pipe" muscle rigidity, autonomic instability, and **serum creatine kinase** (**CK**) above 1000 IU/L. Discontinue offending psychotropics immediately and transfer to an intensive care unit for hydration and **dantrolene** administration. Sample Board Practice Questions. Question 1. Which of the following statements is false regarding schizophrenia? * A. A violent episode can be in response to a hallucination. * B. The presence of a major depressive episode can increase the risk of a suicide attempt. * C. Suicide is attempted in up to 50 percent of patients with schizophrenia. * D. Patients with schizophrenia are more likely to commit a homicide than a member of the general public. Quick Answer. Statement D is false. Key Clue. The phrase "more likely to commit a homicide" drives the answer because medicated patients carry no higher homicide risk than the general public. Best Answer. D. Patients with schizophrenia are more likely to commit a homicide than a member of the general public. Why It Is Correct. When receiving appropriate psychiatric treatment, individuals with **schizophrenia** are no more likely to commit homicide than members of the general population. They are significantly more likely to be victims of violence than perpetrators. Why the Other Choices Are Wrong. * **A**: True statement. Agitation or command hallucinations in untreated psychosis can lead to violent outbursts. * **B**: True statement. Co-occurring **major depressive disorder** is present in up to 80 percent of patients and markedly increases suicide risk. * **C**: True statement. Suicide is attempted by 20 to 50 percent of individuals diagnosed with **schizophrenia**. Test-Taking Pearl. Medicated psychiatric patients do not carry higher homicidal rates than the general public. Stigma-driven distractors claiming elevated homicidal risk are consistently incorrect on board exams. Question 2. According to DSM-5-TR criteria, which of the following are characteristic symptoms of schizophrenia? (Select all that apply) * A. Delusions * B. Hallucinations * C. Compulsive behaviors * D. Disorganized speech Quick Answer. Options A, B, and D are characteristic symptoms. Key Clue. DSM-5-TR Criterion A defines core psychotic domains and explicitly requires at least one of **delusions**, **hallucinations**, or **disorganized speech**. Best Answer. A, B, and D (Delusions, Hallucinations, Disorganized speech). Why It Is Correct. Criterion A for **schizophrenia** requires two or more characteristic symptoms for at least one month: **delusions**, **hallucinations**, **disorganized speech**, grossly disorganized or catatonic behavior, or negative symptoms. At least one required symptom must be delusions, hallucinations, or disorganized speech. Why the Other Choices Are Wrong. * **C**: Compulsive behaviors belong to obsessive-compulsive disorder criteria and are not a defining Criterion A feature of **schizophrenia**. Test-Taking Pearl. Remember the rule of three for Criterion A: at least one core symptom must be **delusions**, **hallucinations**, or **disorganized speech**. Question 3. Laura, a 34-year-old woman diagnosed with schizophrenia 18 months ago, presents for follow-up. She reports feeling "out of it" most of the day since her medication change five weeks ago. She has also gained 10 pounds (4.54 kg). This patient is most likely taking: * A. Quetiapine * B. Aripiprazole * C. Risperidone * D. Ziprasidone Quick Answer. Quetiapine is the most likely medication. Key Clue. The combination of prominent daytime sedation ("out of it") and rapid weight gain points directly to **quetiapine**. Best Answer. A. Quetiapine Why It Is Correct. **Quetiapine** possesses strong histamine H1 receptor antagonism leading to marked sedation and daytime grogginess, alongside significant metabolic side effects including rapid weight gain. Why the Other Choices Are Wrong. * **B**: **Aripiprazole** is a partial dopamine agonist with low sedating properties and minimal weight gain potential. * **C**: While **risperidone** causes weight gain and moderate sedation, **quetiapine** is classic for heavy daytime sedation. * **D**: **Ziprasidone** is largely weight-neutral and requires administration with a 500-calorie meal. Test-Taking Pearl. Match drug side-effect profiles to clinical stems: **quetiapine** and **olanzapine** cause high sedation and weight gain, whereas **ziprasidone** and **aripiprazole** are weight-neutral. Question 4. Indicate whether each of the following clinical findings represents a positive (P) or negative (N) symptom of schizophrenia: * Hallucination * Poverty of speech * Avoidance of eye contact * Disorganized behavior Quick Answer. Hallucination is Positive, Poverty of speech is Negative, Avoidance of eye contact is Negative, Disorganized behavior is Positive. Key Clue. Positive symptoms add abnormal behaviors to normal functioning, whereas negative symptoms represent a loss or deficit of normal human functioning. Best Answer. Hallucination (P), Poverty of speech (N), Avoidance of eye contact (N), Disorganized behavior (P). Why It Is Correct. Positive symptoms reflect an excess of normal function (**hallucinations**, **delusions**, **disorganized behavior**). Negative symptoms reflect a loss of normal function (poverty of speech or alogia, reduced eye contact, avolition, flat affect). Why the Other Choices Are Wrong. Classifying a deficit feature as positive or an additive feature as negative fails basic DSM-5-TR symptom domain rules. Test-Taking Pearl. Think of positive symptoms as additions to perception or behavior, and negative symptoms as subtractions from normal human engagement. Question 5. Mrs. Engle, a 75-year-old woman with a 40-year history of type 2 diabetes mellitus, presents with new-onset visual hallucinations of familiar scenes and people. She hears no voices, remains alert and lucid, acknowledges the images are unreal, and has no cognitive decline or psychiatric history. Her vision has deteriorated over seven years from macular degeneration. What is the most likely diagnosis? * A. Disorganized schizophrenia * B. Early sign of Alzheimer disease * C. Charles Bonnet syndrome * D. Temporal lobe epilepsy Quick Answer. Charles Bonnet syndrome is the correct diagnosis. Key Clue. New visual hallucinations in a cognitively intact, alert elderly patient with severe macular degeneration who retains insight indicates **Charles Bonnet syndrome**. Best Answer. C. Charles Bonnet syndrome Why It Is Correct. **Charles Bonnet syndrome** occurs in visually impaired elderly patients experiencing central visual loss from **macular degeneration** or diabetic retinopathy. Patients perceive vivid visual hallucinations while remaining fully alert, cognitively intact, and aware that the visions are non-existent. Why the Other Choices Are Wrong. * **A**: Late-life **schizophrenia** onset is rare, involves auditory hallucinations and thought disorder, and causes functional decline rather than isolated visual visions. * **B**: Early **Alzheimer disease** features progressive short-term memory impairment rather than isolated complex visual hallucinations with preserved cognition. * **D**: Temporal lobe epilepsy causes brief unformed visual or olfactory auras accompanied by altered consciousness or seizure activity. Test-Taking Pearl. Isolated visual hallucinations in an elderly patient with severe vision loss and preserved cognition is **Charles Bonnet syndrome**, not a primary psychiatric disorder. Question 6. A 22-year-old male with schizophrenia has been taking haloperidol for six months. At this visit, the PMHNP observes involuntary, repetitive facial muscle movements and excessive eye blinking not present at baseline. What is the appropriate next course of action? * A. Measure serum ALT and AST * B. Measure serum creatinine * C. Administer PHQ-9 questionnaire and compare to baseline value * D. Administer AIMS questionnaire and compare to baseline value Quick Answer. Administer the AIMS questionnaire. Key Clue. Involuntary repetitive facial movements and eye blinking on an **FGA** like **haloperidol** indicate **tardive dyskinesia**, requiring quantification with the **AIMS**. Best Answer. D. Administer AIMS questionnaire and compare to baseline value Why It Is Correct. Involuntary facial movements and tongue protrusion after months of **FGA** therapy signify **tardive dyskinesia**. Standard of care requires objective evaluation using the **Abnormal Involuntary Movement Scale** (**AIMS**) to assess severity and compare with baseline scores. Why the Other Choices Are Wrong. * **A**: Liver enzymes assess hepatic function and do not evaluate extrapyramidal movement disorders. * **B**: Serum creatinine measures renal function and is unrelated to motor side effects. * **C**: The PHQ-9 measures depressive severity, not involuntary movement disorders. Test-Taking Pearl. Whenever a patient on long-term antipsychotic therapy develops involuntary facial or lingual movements, the immediate assessment tool is the **AIMS**. Question 7. A 22-year-old male is newly diagnosed with schizophrenia at an outpatient visit with his parents. Which task is most critical for the PMHNP to complete during this visit? * A. Notify the patient's school or employer of the diagnosis * B. Educate the patient on the importance of medication adherence * C. Reassure family members of a low risk of suicide attempt * D. Educate family members of possible increased risk for homicidal tendencies Quick Answer. Educating on medication adherence is the most critical task. Key Clue. Establishing strict medication adherence early in first-episode **schizophrenia** prevents psychotic relapse and brain volume loss. Best Answer. B. Educate the patient on the importance of medication adherence Why It Is Correct. Nonadherence is the leading cause of psychotic relapse, rehospitalization, and progressive functional decline in **schizophrenia**. Educating the patient and family on continuous daily medication adherence is the priority clinical intervention. Why the Other Choices Are Wrong. * **A**: Disclosing psychiatric diagnoses to employers or schools without consent violates HIPAA privacy laws. * **C**: Suicide risk in **schizophrenia** is very high (20% to 50% attempt rate), making claims of low risk false and dangerous. * **D**: Medicated patients do not have increased homicidal tendencies, and emphasizing homicide creates harmful stigma. Test-Taking Pearl. In early psychosis care, the primary intervention to prevent disease exacerbation and disability is patient and family education on medication adherence. Question 8. The PMHNP anticipates that standard treatments used to reduce morbidity in schizophrenia include all of the following EXCEPT: * A. Psychodynamic psychotherapy * B. Cognitive behavioral therapy * C. Assertive community treatment * D. Social skills training Quick Answer. Psychodynamic psychotherapy is excluded. Key Clue. The word "EXCEPT" targets non-evidence-based modalities; **psychodynamic psychotherapy** is not recommended for **schizophrenia**. Best Answer. A. Psychodynamic psychotherapy Why It Is Correct. **Psychodynamic psychotherapy** is not an evidence-based treatment for **schizophrenia**. Unstructured, insight-oriented exploration of unconscious conflicts can heighten anxiety and trigger psychotic decompensation. Why the Other Choices Are Wrong. * **B**: CBT for psychosis is an established evidence-based intervention that helps manage lingering hallucinations and delusions. * **C**: Assertive Community Treatment (**ACT**) provides multidisciplinary community wrap-around care that significantly reduces hospital readmissions. * **D**: Social skills training directly improves daily functioning, social interactions, and negative symptom deficits. Test-Taking Pearl. Avoid unstructured insight-oriented psychodynamic therapy in acute or core psychotic disorders; rely instead on CBT for psychosis, ACT teams, and social skills training. Question 9. A 34-year-old male presents to the emergency department with severe muscle rigidity, hyperthermia, and altered mental status. He has taken fluphenazine for three weeks and recently started lithium. What laboratory finding is expected? * A. HbA1c greater than 8.5% * B. Platelet count of 650,000 * C. Serum creatine kinase greater than 1000 IU/L * D. ALT to AST ratio greater than 5 to 1 Quick Answer. Serum creatine kinase greater than 1000 IU/L is expected. Key Clue. The presentation of hyperthermia, muscle rigidity, and altered mental status ("hot, stiff, and out of it") defines **NMS**, which causes severe rhabdomyolysis and elevated **CK**. Best Answer. C. Serum creatine kinase greater than 1000 IU/L Why It Is Correct. **Neuroleptic Malignant Syndrome** (**NMS**) causes intense muscle breakdown (rhabdomyolysis), resulting in extreme elevations of **serum creatine kinase** (**CK**) typically exceeding 1000 IU/L and reaching up to 100,000 IU/L. Why the Other Choices Are Wrong. * **A**: Elevated HbA1c indicates chronic hyperglycemia and metabolic syndrome, not acute rhabdomyolysis. * **B**: Thrombocytosis is unrelated to antipsychotic-induced **NMS**. * **D**: Transaminase ratio changes indicate liver pathology rather than acute skeletal muscle necrosis. Test-Taking Pearl. Remember the **NMS** triad: "hot, stiff, and out of it." The hallmark diagnostic laboratory marker is a dramatically elevated **serum creatine kinase** (**CK**). Next. Topic. Etiological risk factors. Bottom Line. 1. **General population prevalence**: **Schizophrenia** affects 0.7% of the population worldwide, occurring in equal proportions among **men** and **women**. 2. **Genetic risk hierarchy**: Monozygotic twin concordance is 50%, dual affected parents carry a 40% risk, a single affected parent carries a 12% risk, a non-twin sibling carries an 8% risk, while most individuals diagnosed with **schizophrenia** have no positive family history of psychosis. 3. **Age of onset divergence**: Peak onset for **men** is **10 to 25 years of age**, whereas peak onset for **women** is **25 to 35 years of age** with a secondary smaller peak occurring after age **40 years**. Onset is rare before age **10 years** or after age **60 years**. 4. **Environmental and gestational risk factors**: Risk is significantly increased by **winter** and **spring birth seasons**, prenatal exposure to **influenza**, **perinatal hypoxia**, maternal starvation during pregnancy, and **greater paternal age** at conception. 5. **Neurochemical etiology**: **Schizophrenia** is a complex biological brain disease involving multi-pathway neurotransmitter dysregulation across **dopamine**, **serotonin**, **glutamate**, **GABA**, **acetylcholine**, **nicotine**, and **norepinephrine**. 6. **Disproven etiology myths**: The "schizophrenic-genic mother" theory is completely disproven. Psychosocial stress alters disease progression and triggers relapse, but does not cause the underlying biological pathology. 7. **Mortality and comorbidity**: Life expectancy is reduced by up to 20% (dying up to 25 years earlier), driven heavily by **tobacco addiction** (90% prevalence) and cardiovascular comorbidities. Suicide is attempted by 20% to 50% of patients, with a 5% long-term completed suicide rate. 8. **First-line intervention**: **Second-generation antipsychotics** (**SGAs**) are **first-line** pharmacotherapy due to equivalent positive symptom control, superior negative symptom efficacy, and reduced extrapyramidal risk compared to **first-generation antipsychotics** (**FGAs**). High-Yield Concept Map: Etiology and Risk Factors. Biological and Genetic Risk Hierarchy. - **What it is**: **Schizophrenia** is a biological, neurodevelopmental brain disorder with a strong multifactorial genetic basis. - **Why boards care**: ANCC and AANPCB exams test precise genetic concordance percentages, age of onset gender splits, and lifespan boundaries to differentiate biological facts from outdated clinical myths. - **Must know criteria and numbers**: - General population prevalence: 0.7%. - Gender ratio: **Men** equal **women** in overall prevalence. - Age of onset: Peak for **men** is **10 to 25 years of age**. Peak for **women** is **25 to 35 years of age**, with a secondary peak after age **40 years**. Onset before age **10 years** or after age **60 years** is extremely rare. - Genetic concordance rates: - **Monozygotic twin**: 50% risk (50% likelihood of not developing the illness). - **Both parents affected**: 40% risk (60% likelihood of not developing the illness). - **One parent affected**: 12% risk. - **Non-twin sibling**: 8% risk. - **No family history**: Most individuals diagnosed with **schizophrenia** have no family history of psychosis. - **Typical board clue**: A young male in his late teens presenting with gradual decline in grooming and social withdrawal, or a question asking to calculate relative risk for offspring or twins. - **First-line approach**: Initiate early diagnostic evaluation and **first-line** treatment with **second-generation antipsychotics** (**SGAs**) while providing immediate psychoeducation on **medication adherence**. - **When the answer changes**: - **Board trap**: Do not select poor parenting, family communication styles, or "schizophrenic-genic mothers" as the etiology. Although pathologic family behaviors increase emotional stress and relapse risk, the illness is strictly biological. - **Board trap**: Distinguish **schizophrenia** (symptoms lasting at least 6 months including 1 month of active criteria) from **schizophreniform disorder** (symptoms lasting 1 to 6 months) and **brief psychotic disorder** (symptoms lasting less than 1 month). - **Safety alert**: **Suicide risk** is extremely high. Lifetime suicide attempts occur in 20% to 50% of patients, with 5% completing suicide. Co-occurring **major depressive disorder** (occurring in up to 80% of patients over their lifetime) significantly elevates suicide attempt risk. Environmental, Prenatal, and Perinatal Risk Factors. - **What it is**: Non-genetic gestational and environmental insults that impair fetal neurodevelopment and early brain formation. - **Why boards care**: Board questions evaluate recognition of non-hereditary risk factors that increase vulnerability to psychotic spectrum disorders. - **Must know risk triggers**: - Season of birth: Statistically increased incidence among individuals born in **winter** and **spring** months. - Gestational infection: Fetal exposure to maternal **influenza** during pregnancy. - Obstetric complications: **Perinatal hypoxia**, birth complications, and maternal starvation during pregnancy. - Demographics: **Greater paternal age** at the time of conception. - **Typical board clue**: A clinical vignette describing a patient born in late winter whose gestation was complicated by severe maternal viral infection or delivery hypoxia. - **Safety alert**: Non-tobacco **substance use disorder** occurs in 50% of patients and **alcohol use disorder** in 40%, heavily triggering psychotic relapses and treatment non-adherence. - **Safety alert**: **Tobacco addiction** occurs in 90% of patients with **schizophrenia**. Hydrocarbon byproducts in tobacco smoke induce the **CYP1A2** enzyme, accelerating clearance and lowering serum concentrations of **clozapine** and **olanzapine**. Inpatient hospital admission or abrupt smoking cessation removes **CYP1A2** induction, causing blood levels of **clozapine** or **olanzapine** to rise rapidly and induce toxicity unless doses are reduced. Neurochemical and Neuroanatomical Etiology. - **What it is**: Widespread dysregulation across central neurotransmitter networks without a single isolated anatomical lesion. - **Why boards care**: Questions test the physiological basis of positive versus negative symptoms and the rationale for selecting **second-generation antipsychotics**. - **Must know neurochemical pathways**: - **Dopamine hypothesis**: Mesolimbic pathway hyperactivity drives positive symptoms; mesocortical pathway hypoactivity drives negative and cognitive symptoms. - **Serotonin dysregulation**: Combined 5-HT2A receptor blockade in **SGAs** reduces extrapyramidal symptoms and improves negative symptoms. - **Other neurotransmitters**: **Glutamate**, **GABA**, **acetylcholine**, **nicotine**, and **norepinephrine** show widespread pathological alterations. - **Compare and distinguish**: - **Positive symptoms** vs **Negative symptoms**: - **Positive symptoms**: Delusions, hallucinations, disorganized speech, bizarre motor behavior. These represent additions to normal perception. Present during active phases. Well-controlled by both **first-generation antipsychotics** (**FGAs**) and **second-generation antipsychotics** (**SGAs**). - **Negative symptoms**: Avolition, flat affect, alogia (poverty of speech), thought blocking, social withdrawal, decreased eye contact. These represent deficits in normal functioning. Present during prodromal and residual phases. Highly disabling over time. Poorly controlled by **FGAs**, better managed by **SGAs**. Board-Style Sample Practice Questions. Question 1. Which of the following statements is false regarding schizophrenia? - A. A violent episode can be in response to a hallucination. - B. The presence of a major depressive disorder episode can increase the risk of a suicide attempt. - C. Suicide is attempted in up to 50 percent of patients with schizophrenia. - D. Patients with schizophrenia are more likely to commit a homicide than a member of the general public. Pause. Answer. **Best answer**: D **Why it is correct**: When properly treated and medicated, patients with **schizophrenia** are no more likely to commit homicide than members of the general public. **Why the other choices are wrong**: - **A**: Incorrect because it is a true statement; unmedicated patients experiencing active psychosis or command hallucinations may display violent behaviors in response to hallucinatory perceptions. - **B**: Incorrect because it is a true statement; co-occurring **major depressive disorder** occurs in up to 80 percent of patients with **schizophrenia** over their lifetime and markedly elevates suicide risk. - **C**: Incorrect because it is a true statement; lifetime suicide attempts occur in 20 percent to 50 percent of individuals diagnosed with **schizophrenia**. **Test-taking pearl**: Reject societal stigma on board exams. Medicated patients with **schizophrenia** are far more likely to be victims of violence than perpetrators of homicide. Question 2. According to DSM-5-TR criteria, which of the following are characteristic symptoms of schizophrenia? (Select all that apply) - A. Delusions - B. Hallucinations - C. Compulsive behaviors - D. Disorganized speech Pause. Answer. **Best answer**: A, B, and D **Why it is correct**: According to DSM-5-TR Criterion A for **schizophrenia**, characteristic symptoms include **delusions**, **hallucinations**, **disorganized speech**, grossly disorganized or catatonic behavior, and negative symptoms. At least two characteristic symptoms must be present for a significant portion of time during a one-month period, and at least one core symptom must be **delusions**, **hallucinations**, or **disorganized speech**. **Why the other choices are wrong**: - **C**: Incorrect because compulsive behaviors are characteristic features of **obsessive-compulsive disorder** (**OCD**), not core diagnostic criteria for **schizophrenia**. **Test-taking pearl**: Memorize the mandatory diagnostic anchor rule: a diagnosis of **schizophrenia** requires at least one core positive symptom from the triad of **delusions**, **hallucinations**, or **disorganized speech**. Question 3. A 22-year-old male patient is newly diagnosed with schizophrenia and presents for an outpatient appointment accompanied by his parents. Which of the following does the PMHNP realize is the most critical task to complete at this visit? - A. Notify the patient's school or workplace of the new diagnosis. - B. Educate the patient on the importance of medication adherence. - C. Reassure family members of a low overall risk of suicide attempt. - D. Educate family members of a possible increased risk for homicidal tendencies. Pause. Answer. **Best answer**: B **Why it is correct**: **First-line** psychoeducation regarding strict **medication adherence** is the single most critical intervention in early **schizophrenia**. Adherence reduces the rate of psychotic relapses, minimizes step-wise cognitive and functional decline after each episode, and lowers rehospitalization rates. **Why the other choices are wrong**: - **A**: Incorrect because notifying an employer or academic institution without explicit written patient consent violates HIPAA privacy regulations and patient confidentiality. - **C**: Incorrect because telling families suicide risk is low is factually false and unsafe; up to 50 percent of patients attempt suicide. - **D**: Incorrect because educating families about homicidal tendencies reinforces false stigma; treated patients carry no higher homicide risk than the general public. **Test-taking pearl**: Early adherence counseling prevents illness relapse. Each psychotic relapse causes cumulative, irreversible neurofunctional decline from baseline. Next Study Step. The next best topic to study is **Fitzgerald Chapter 10: Antipsychotic Psychopharmacology and Adverse Effect Monitoring**. This builds directly on etiology by mastering **FGA** vs **SGA** receptor binding, **clozapine** **ANC** protocols, **NMS**, **EPS**, and **tardive dyskinesia** management. Next. End of this drive.